7 results about "Lipid binding" patented technology

The present invention relates to a method for reducing lipid binding of brazzein and / or to method for improving digestibility of brazzein in a subject's digestive track as well as to a modified brazzein polypeptide and uses of it and to a nucleic acid encoding the same.

The present invention relates to a method for reducing lipid binding of brazzein and / or to method for improving digestibility of brazzein in a subject's digestive track as well as to a modified brazzein polypeptide and uses of it and to a nucleic acid encoding the same.

This invention relates to the fields of environmental and bioanalytical technology, and particularly to a method for simultaneous pretreatment and detection of bisphenol S and bisphenol AF in biological tissues. The technical solution includes a framework process for simultaneous pretreatment and detection of bisphenol S and bisphenol AF in biological tissues. This invention establishes a dual-solvent secondary extraction system composed of n-hexane and methyl tert-butyl ether, achieving differentiated adaptation to different tissue matrices. By combining the advantages of non-polar and moderately polar solvents, it can simultaneously handle the relatively highly polar bisphenol S and the relatively non-polar bisphenol AF in a single extraction process. Furthermore, this method sets key physical parameters during the extraction process according to the histological characteristics of each organ. For heart and lung tissues, specific ultrasonic power is used to ensure thorough cell disruption; while for liver and spleen with high lipid content, different power and time are used to ensure the full release of lipid-bound target substances.

Methods of using a lipid binding protein molecule to treat a subject having one or more conditions or at risk of one or more conditions. The method generally includes measuring ApoA-I levels and / or HDL cholesterol levels in the subject, and administering one or more doses of the lipid binding protein molecule to the subject if the measured ApoA-I levels are below a target ApoA-I level or target ApoA-I range, and / or the measured HDL levels are below a target HDL level.

This disclosure provides therapeutic nanodiscs comprising a lipid-binding polypeptide, a lipid bilayer, and a therapeutic agent, wherein the therapeutic agent may be used to treat, prevent, or diagnose central nervous system diseases, disorders, injuries, or injuries. The lipid bilayer may be 1,2-dimiristoyl-sn-glycero-3-phosphocholine (DMPC), and the therapeutic agent may be a nucleic acid polymer. Furthermore, methods for administering therapeutic nanodiscs to treat, prevent, or diagnose central nervous system diseases, disorders, injuries, or injuries, as well as the use of such therapeutic nanodiscs, are provided.